Culture Biosciences Raises $80M in Series B Funding

Culture Biosciences

Culture Biosciences, a South San Francisco, CA-based company enabling biotech firms to develop and scale manufacturing processes in the cloud, raised $80m in Series B financing.

The round was led by Northpond Ventures with participation from Synthesis Capital and existing investors Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, Box Group, Verily Life Sciences, and Section 32. In conjunction with the funding, Andrew Lee, Ph.D., of Northpond Ventures will join Culture’s Board of Directors.

Led by Will Patrick, CEO and co-founder, Culture Biosciences is a technology company offering biotechnology companies a way to do biomanufacturing R&D. By leveraging its cloud bioreactor platform, bioprocess scientists can spend more time designing and analyzing experiments. Culture’s cloud bioreactors offer full control of experimental design and allow real-time monitoring and process changes. Beyond generating data more quickly, the platform provides advanced data visualization and analytics tools to generate new insights into bioprocesses.

To date, Culture has raised over $100 million. This new round of funding will be used to build and scale 5L and 250L cloud bioreactors, supporting customer demand for larger quantities of material to use for testing and regulatory approval.

FinSMEs

14/10/2021